Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival

The purpose of this study was to investigate the impact of hospital type determined at primary treatment and find possible predictors of survival in a cohort of patients with advanced epithelial ovarian cancer (EOC) who recurred twice and received three lines of treatment during eight-year follow-up. Using the Norwegian Cancer Registry, the authors identified 174 women with FIGO Stage IIIC EOC diagnosed in 2002. First-line treatment consisted of up-front debulking surgery and chemotherapy, received in either a teaching hospital (TH, n = 84) or a non-teaching hospital (NTH, n=90). After recurrence all patients in Norway are equally consulted at TH. Survival determined for three time intervals (TI): TI-1, from end date of first-line treatment to first recurrence or death, TI-2, from beginning of second-line treatment until second recurrence or death, and TI-3, from beginning of third-line treatment to death or end of follow-up. Extensive surgery carried out in TH followed by at least six cycles of platinol-taxan chemotherapy resulted in longer survival in the TH group during TI-1. Altogether, the majority of those who receive treatment for recurrences were primary better debulked with following platinol-taxane chemotherapy. Survival in TI-2 was influenced by platinol-sensitivity. During TI-3 the majority (96%) had good performance status and their mean age at primary diagnosis at either hospital type was 57 years. Extensive primary surgery at TH, platinol sensitivity, age, and performance status were predictors of survival in this cohort.

Recurrent ovarian neoplasm; Follow-up; Second recurrence; Third treatment line; Predictors of survival.

[1] Vernooij F., Heintz P., Witteveen E., van der Graaf Y.: “The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review”. Gynecol. Oncol., 2007, 105, 801.

[2] Kumpulainen S., Kuoppala T., Leminen A., Penttinen J., Puistola U., Pukkala E., et al.: “Surgical treatment of ovarian cancer in different hospital categories--a prospective nation-wide study in Finland”. Eur. J. Cancer, 2006, 42, 388.

[3] Woodman C., Baghdady A., Collins S., Clyma J.A.: “What changes in the organisation of cancer services will improve the outcome for women with ovarian cancer?” Br. J. Obstet. Gynaecol., 1997, 104, 135.

[4] Tingulstad S., Skjeldestad F.E., Halvorsen T.B., Hagen B.: “Survival and prognostic factors in patients with ovarian cancer”. Obstet. Gynecol., 2003, 101, 885.

[5] Engelen M.J., van der Zee A.G., de Vries E.G., Willemse P.H.: “Debulking surgery for ovarian epithelial cancer performed by a gynaecological oncologist improved survival compared with less specialised surgeons”. Cancer Treat. Rev., 2006, 32, 320.

[6] Marth C., Hiebl S., Oberaigner W., Winter R., Leodolter S., Sevelda P.: “Influence of department volume on survival for ovarian cancer: results from a prospective quality assurance program of the Austrian Association for Gynecologic Oncology”. Int. J. Gynecol. Cancer, 2009, 19, 94.

[7] Aune G., Torp S.H., Syversen U., Hagen B., Tingulstad S.: “Ten years' experience with centralized surgery of ovarian cancer in one health region in Norway”. Int. J. Gynecol. Cancer, 2012, 22, 226.

[8] Tingulstad S., Skjeldestad F.E., Hagen B.: “The effect of centralization of primary surgery on survival in ovarian cancer patients”. Obstet. Gynecol., 2003, 102, 499.

[9] Fago-Olsen C.L., Hogdall C., Kehlet H., Christensen I.J., Ottesen B.: “Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey”. Acta Obstet. Gynecol. Scand., 2011, 90, 273.

[10] Paulsen T., Kjaerheim K., Kaern J., Tretli S., Trope C.: “Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals”. Int. J. Gynecol. Cancer, 2006, 16, 11.

[11] Paulsen T., Szczesny W., Kaern J., Vistad I., Tropé C.: “Improved 8-year survival for patients with stage IIIC ovarian cancer operated on at teaching hospitals: Population-based study in Norway 2002”. Clinical Ovarian and Other Gynecologic Cancer, 2013, 28, 60.

[12] Markman M., Hoskins W.: “Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population”. J. Clin. Oncol., 1992, 10, 513.

[13] Colombo N., Gore M.: “Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy”. Crit. Rev. Oncol. Hematol., 2007, 64, 129.

[14] Markman M., Markman J., Webster K., Zanotti K., Kulp B., Peterson G., et al.: “Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design”. J. Clin. Oncol., 2004, 22, 3120.

[15] Hanker L.C., Loibl S., Burchardi N., Pfisterer J., Meier W., Pujade- Lauraine E., et al.: “The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinumbased therapy”. Ann. Oncol., 2012, 23, 2605.

[16] Vergote I., Finkler N., del C.J., Lohr A., Hunter J., Matei D., et al.: “Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer”. Eur. J. Cancer, 2009, 45, 2324.

[17] Tingulstad S., Halvorsen T., Norstein J., Hagen B., Skjeldestad F.E.: “Completeness and accuracy of registration of ovarian cancer in the cancer registry of Norway”. Int. J. Cancer, 2002, 98, 907.

[18] Harvei S., Tretli S., Langmark F.: “Quality of prostate cancer data in the cancer registry of Norway”. Eur. J. Cancer, 1996, 32A, 104.

[19] Larsen I.K., Småstuen M., Johannesen T.B., Langmark F., Parkin D.M., Bray F., et al.: “Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness”. Eur. J. Cancer, 2009, 45, 1218.

[20] Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R.: “A new method of classifying prognostic comorbidity in longitudinal studies: development and validation”. J. Chronic Dis., 1987, 40, 373.

[21] Sundar T.: “Shrinking cancerous tumours by applying heat”. Tidsskr. Nor. Laegeforen, 2002, 122, 2563.

[22] Hjertaker B.T., Froystein T., Schem B.C.: “A thermometry system for quality assurance and documentation of whole body hyperthermia procedures”. Int. J. Hyperthermia, 2005, 21, 45.

[23] Munstedt K., von G.R., Misselwitz B., Zygmunt M., Stillger R., Kunzel W.: “Centralizing surgery for gynecologic oncology--a strategy assuring better quality treatment?” Gynecol. Oncol., 2003, 89, 4.

[24] Schorge J.O., Eisenhauer E.E., Chi D.S.: “Current surgical management of ovarian cancer”. Hematol. Oncol. Clin. North Am., 2012, 26, 93.

[25] Pfisterer J.: “Recurrent ovarian cancer”. Onkologie, 2004, 27, 7.

[26] Markman M., Lewis J.L., Jr., Saigo P., Hakes T., Rubin S., Jones W., et al.: “Impact of age on survival of patients with ovarian cancer”. Gynecol. Oncol., 1993, 49, 236.

[27] Oksefjell H., Sandstad B., Trope C.: “The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer”. Ann. Oncol., 2009, 20, 286.

[28] Williams C., Simera I., Bryant A.: “Tamoxifen for relapse of ovarian cancer”. Cochrane Database Syst. Rev., 2010, 3, CD001034.

[29] Trope C., Marth C., Kaern J.: “Tamoxifen in the treatment of recurrent ovarian carcinoma”. Eur. J. Cancer, 2000, 36, S59.

[30] Charlton B.G., Taylor P.R., Proctor S.J.: “The PACE (populationadjusted clinical epidemiology) strategy: a new approach to multicentred clinical research”. QJM, 1997, 90, 147.